에스트로겐 수용체 양성 유방암 치료 시장 규모, 점유율, 동향 분석 보고서 : 치료별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Estrogen Receptor Positive Breast Cancer Treatment Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Targeted Therapy), By End-use (Hospitals, Specialty Clinics), By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,302,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,698,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,488,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

에스트로겐 수용체 양성 유방암 치료 시장 성장 및 동향:

Grand View Research, Inc.의 최신 보고서에 따르면, 세계 에스트로겐 수용체 양성 유방암 치료 시장은 2030년까지 337억 달러에 달할 것으로 예상되며, 2024년부터 2030년까지 연평균 7.89% 성장할 것으로 예상됩니다.

이 시장에는 이 아형 유방암을 표적화하고 관리하기 위해 특별히 고안된 다양한 치료 옵션이 포함됩니다.

약물 개발의 혁신은 ER 유방암 치료 시장에 큰 영향을 미치고 있습니다. 새로운 치료법에는 새로운 아로마타제 억제제, 선택적 에스트로겐 수용체 분해제(SERD), 표적치료제 등이 있습니다. 예를 들어, 2023년 1월 FDA는 ESR1 변이가 있는 전이성 에스트로겐 수용체 양성, HER2 음성 유방암에 대한 경구용 처방약인 오셀듀를 승인하여 개인 맞춤형 치료 전략으로의 전환을 강조하고 있습니다.

제약사, 생명공학 기업, 연구기관의 전략적 제휴 및 협력 관계는 ER 유방암 치료 시장에 큰 영향을 미칩니다. 예를 들어, 2024년 6월 메나리니 그룹이 인실리코 메디신과 신규 KAT6A 억제제 개발에 대한 라이선스 계약을 체결한 것은 암 치료 트렌드를 발전시키기 위한 공동 노력의 추세를 강조합니다. 이러한 파트너십은 종종 약물 개발의 가속화와 보다 종합적인 치료 옵션으로 이어져 전체 ER 유방암 치료 환경을 강화하고 시장 확대에 기여하고 있습니다.

에스트로겐 수용체 양성 유방암 치료 시장 보고서 하이라이트

• 치료법별로는 호르몬 요법이 2023년 시장을 주도했습니다. 그 이유는 환자 예후 개선 효과, 화학요법 등 다른 치료법에 비해 우수한 부작용 프로파일, 유지요법으로서의 장기적 적용 가능성, 가이드라인의 강력한 지지, 최소침습적 치료법에 대한 환자 선호도 증가, 비용 효율적인 치료법을 뒷받침하는 경제적 고려사항, 개인화된 의료 접근법을 촉진하는 바이오마커 테스트의 발전 를 촉진하는 바이오마커 검사의 발전, 이 카테고리의 새로운 치료 옵션으로 이어지는 지속적인 연구 등이 있습니다.
• 최종사용자별로는 병원이 2023년 62.48%의 가장 큰 매출 점유율로 시장을 장악했습니다. 그 이유는 다학제적 팀의 종합적인 치료 제공 능력, 임상시험을 포함한 첨단 치료에 대한 접근성, 복잡한 요구를 가진 고령 환자를 선호하는 인구통계학적 요인, 보험 적용 및 비용 효율성에 대한 경제적 고려, 환자 결과를 개선하기 위한 연구 개발 노력에서 매우 중요한 역할 등을 꼽을 수 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 에스트로겐 수용체 양성 유방암 치료 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상부 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 에스트로겐 수용체 양성 유방암 치료 시장 분석 툴
  • 업계 분석 - Porter's Five Forces 분석
  • PESTEL 분석

제4장 에스트로겐 수용체 양성 유방암 치료 시장 : 치료별 추정·동향 분석

• 세계의 에스트로겐 수용체 양성 유방암 치료 시장 : 치료 대시보드
• 세계의 에스트로겐 수용체 양성 유방암 치료 시장 : 치료 변동 분석
• 세계의 에스트로겐 수용체 양성 유방암 치료 시장 : 치료별 매출
• 화학요법
• 표적요법
• 호르몬요법
• 방사선 치료
• 기타

제5장 에스트로겐 수용체 양성 유방암 치료 시장 : 최종 용도별 추정·동향 분석

• 세계의 에스트로겐 수용체 양성 유방암 치료 시장 : 최종 용도 대시보드
• 세계의 에스트로겐 수용체 양성 유방암 치료 시장 : 최종 용도 변동 분석
• 세계의 에스트로겐 수용체 양성 유방암 치료 시장 : 최종 용도별 매출
• 병원
• 전문 클리닉
• 기타

제6장 에스트로겐 수용체 양성 유방암 치료 시장 : 치료 및 최종 용도별 지역별 추정·동향 분석

• 지역 대시보드
• 시장 규모, 예측 동향 분석, 2018년에서 2030년 :
• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 아프리카

제7장 경쟁 상황

• 기업/경쟁 분류
• 벤더 상황
  • 주요 판매대리점 및 채널 파트너 리스트
  • 주요 기업의 시장 점유율 분석, 2023년
  • Radius Health, Inc.
  • Sanofi
  • F. Hoffmann-La Roche Ltd
  • AstraZeneca
  • Lilly
  • EQRx, Inc.
  • Gilead Sciences, Inc.
  • Sermonix Pharmaceuticals
  • Tyme Limited
  • Genentech, Inc.

ksm

영문 목차

영문목차

Estrogen Receptor Positive Breast Cancer Treatment Market Growth & Trends:

The global estrogen receptor positive breast cancer treatment market is anticipated to reach USD 33.7 billion by 2030 and is projected to grow at a CAGR of 7.89% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market includes a variety of therapeutic options specifically designed to target and manage this subtype of breast cancer.

Innovations in drug development are significantly impacting the ER+ breast cancer treatment market. New therapies include novel aromatase inhibitors, selective estrogen receptor degraders (SERDs), and targeted treatments. For instance, in January 2023, the FDA authorized Orserdu, an oral prescription for metastatic estrogen receptor-positive, HER2-negative breast cancer with an ESR1 mutation, underscoring a shift towards personalized treatment strategies.

Strategic collaborations and partnerships between pharmaceutical companies, biotechnology firms, and research institutions significantly impact the market for ER+ breast cancer treatment. For instance, in June 2024, Menarini Group's licensing agreement with Insilico Medicine to develop a new KAT6A inhibitor underscores the trend toward collaborative efforts to advance oncology treatments. These partnerships often lead to accelerated drug development and more comprehensive treatment options, enhancing the overall treatment landscape for ER+ breast cancer and contributing to market expansion.

Estrogen Receptor Positive Breast Cancer Treatment Market Report Highlights:

• Based on treatment, hormonal therapy dominated the market in 2023 due to its efficacy in improving patient outcomes, favorable side effect profiles compared with other modalities such as chemotherapy, long-term applicability as maintenance therapy, strong guideline support, patient preference trends towards less invasive options, economic considerations favoring cost-effective treatments, advancements in biomarker testing facilitating personalized medicine approaches, and continuous research leading to new therapeutic options within this category.
• Based on end use, hospitals dominated the market with the largest revenue share of 62.48% in 2023 due to their ability to provide comprehensive care through multidisciplinary teams, access to advanced treatments including clinical trials, demographic factors favoring older patients with complex needs, economic considerations regarding insurance coverage and cost efficiency, and their pivotal role in R&D efforts to improve patient outcomes.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Treatment
  • 1.2.2. End Use
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Treatment Outlook
  • 2.2.2. End Use Outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Estrogen Receptor Positive Breast Cancer Treatment Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. High incidence and prevalence of ER+ breast cancer
    • 3.2.1.2. Availability of endocrine therapies targeting ER
    • 3.2.1.3. Increasing adoption of targeted therapies
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Limited treatment options for resistant cases
    • 3.2.2.2. High costs associated with advanced therapies
• 3.3. Estrogen Receptor Positive Breast Cancer Treatment Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Estrogen Receptor Positive Breast Cancer Treatment Market: Treatment Estimates & Trend Analysis

• 4.1. Global Estrogen Receptor Positive Breast Cancer Treatment Market: Treatment Dashboard
• 4.2. Global Estrogen Receptor Positive Breast Cancer Treatment Market: Treatment Movement Analysis
• 4.3. Global Estrogen Receptor Positive Breast Cancer Treatment Market by Treatment, Revenue
• 4.4. Chemotherapy
  • 4.4.1. Chemotherapy market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Targeted Therapy
  • 4.5.1. Targeted therapy market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Hormonal Therapy
  • 4.6.1. Hormonal therapy market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Radiation Therapy
  • 4.7.1. Radiation therapy market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Other
  • 4.8.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Estrogen Receptor Positive Breast Cancer Treatment Market: End Use Estimates & Trend Analysis

• 5.1. Global Estrogen Receptor Positive Breast Cancer Treatment Market: End Use Dashboard
• 5.2. Global Estrogen Receptor Positive Breast Cancer Treatment Market: End Use Movement Analysis
• 5.3. Global Estrogen Receptor Positive Breast Cancer Treatment Market Estimates and Forecasts, By End Use, Revenue (USD Million)
• 5.4. Hospitals
  • 5.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Specialty Clinics
  • 5.5.1. Specialty clinics market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Other
  • 5.6.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Estrogen Receptor Positive Breast Cancer Treatment Market: Regional Estimates & Trend Analysis by Treatment, and End Use

• 6.1. Regional Dashboard
• 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.3. North America
  • 6.3.1. U.S.
    • 6.3.1.1. Key country dynamics
    • 6.3.1.2. Regulatory framework/ reimbursement structure
    • 6.3.1.3. Competitive scenario
    • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.2. Canada
    • 6.3.2.1. Key country dynamics
    • 6.3.2.2. Regulatory framework/ reimbursement structure
    • 6.3.2.3. Competitive scenario
    • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.3. Mexico
    • 6.3.3.1. Key country dynamics
    • 6.3.3.2. Regulatory framework/ reimbursement structure
    • 6.3.3.3. Competitive scenario
    • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 6.4. Europe
  • 6.4.1. UK
    • 6.4.1.1. Key country dynamics
    • 6.4.1.2. Regulatory framework/ reimbursement structure
    • 6.4.1.3. Competitive scenario
    • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Germany
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Regulatory framework/ reimbursement structure
    • 6.4.2.3. Competitive scenario
    • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. France
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Regulatory framework/ reimbursement structure
    • 6.4.3.3. Competitive scenario
    • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.4. Italy
    • 6.4.4.1. Key country dynamics
    • 6.4.4.2. Regulatory framework/ reimbursement structure
    • 6.4.4.3. Competitive scenario
    • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.5. Spain
    • 6.4.5.1. Key country dynamics
    • 6.4.5.2. Regulatory framework/ reimbursement structure
    • 6.4.5.3. Competitive scenario
    • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.6. Norway
    • 6.4.6.1. Key country dynamics
    • 6.4.6.2. Regulatory framework/ reimbursement structure
    • 6.4.6.3. Competitive scenario
    • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.7. Sweden
    • 6.4.7.1. Key country dynamics
    • 6.4.7.2. Regulatory framework/ reimbursement structure
    • 6.4.7.3. Competitive scenario
    • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.8. Denmark
    • 6.4.8.1. Key country dynamics
    • 6.4.8.2. Regulatory framework/ reimbursement structure
    • 6.4.8.3. Competitive scenario
    • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Japan
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.2. China
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. India
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.4. Australia
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework/ reimbursement structure
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.5. South Korea
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Regulatory framework/ reimbursement structure
    • 6.5.5.3. Competitive scenario
    • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.6. Thailand
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Regulatory framework/ reimbursement structure
    • 6.5.6.3. Competitive scenario
    • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Latin America
  • 6.6.1. Brazil
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.2. Argentina
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. MEA
  • 6.7.1. South Africa
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.2. Saudi Arabia
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.3. UAE
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.4. Kuwait
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Company/Competition Categorization
• 7.2. Vendor Landscape
  • 7.2.1. List of key distributors and channel partners
  • 7.2.2. Key company market share analysis, 2023
  • 7.2.3. Radius Health, Inc.
    • 7.2.3.1. Company overview
    • 7.2.3.2. Financial performance
    • 7.2.3.3. Product benchmarking
    • 7.2.3.4. Strategic initiatives
  • 7.2.4. Sanofi
    • 7.2.4.1. Company overview
    • 7.2.4.2. Financial performance
    • 7.2.4.3. Product benchmarking
    • 7.2.4.4. Strategic initiatives
  • 7.2.5. F. Hoffmann-La Roche Ltd
    • 7.2.5.1. Company overview
    • 7.2.5.2. Financial performance
    • 7.2.5.3. Product benchmarking
    • 7.2.5.4. Strategic initiatives
  • 7.2.6. AstraZeneca
    • 7.2.6.1. Company overview
    • 7.2.6.2. Financial performance
    • 7.2.6.3. Product benchmarking
    • 7.2.6.4. Strategic initiatives
  • 7.2.7. Lilly
    • 7.2.7.1. Company overview
    • 7.2.7.2. Financial performance
    • 7.2.7.3. Product benchmarking
    • 7.2.7.4. Strategic initiatives
  • 7.2.8. EQRx, Inc.
    • 7.2.8.1. Company overview
    • 7.2.8.2. Financial performance
    • 7.2.8.3. Product benchmarking
    • 7.2.8.4. Strategic initiatives
  • 7.2.9. Gilead Sciences, Inc.
    • 7.2.9.1. Company overview
    • 7.2.9.2. Financial performance
    • 7.2.9.3. Product benchmarking
    • 7.2.9.4. Strategic initiatives
  • 7.2.10. Sermonix Pharmaceuticals
    • 7.2.10.1. Company overview
    • 7.2.10.2. Financial performance
    • 7.2.10.3. Product benchmarking
    • 7.2.10.4. Strategic initiatives
  • 7.2.11. Tyme Limited
    • 7.2.11.1. Company overview
    • 7.2.11.2. Financial performance
    • 7.2.11.3. Product benchmarking
    • 7.2.11.4. Strategic initiatives
  • 7.2.12. Genentech, Inc.
    • 7.2.12.1. Company overview
    • 7.2.12.2. Financial performance
    • 7.2.12.3. Product benchmarking
    • 7.2.12.4. Strategic initiatives

관련자료